Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) COO Susanna Gatti High sold 10,163 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at $5,256,821.36. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Susanna Gatti High also recently made the following trade(s):
- On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.01, for a total transaction of $1,042,842.87.
- On Wednesday, June 12th, Susanna Gatti High sold 40,000 shares of Dyne Therapeutics stock. The shares were sold at an average price of $33.36, for a total transaction of $1,334,400.00.
- On Monday, June 10th, Susanna Gatti High sold 80,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $30.24, for a total transaction of $2,419,200.00.
- On Thursday, May 16th, Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26.
Dyne Therapeutics Stock Up 0.0 %
Shares of NASDAQ DYN opened at $33.92 on Thursday. The firm has a 50-day simple moving average of $29.56 and a 200-day simple moving average of $24.26. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -8.54 and a beta of 1.06. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $36.60.
Institutional Investors Weigh In On Dyne Therapeutics
Hedge funds have recently modified their holdings of the business. DekaBank Deutsche Girozentrale increased its position in Dyne Therapeutics by 50.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the company’s stock worth $1,710,000 after purchasing an additional 20,000 shares during the last quarter. RA Capital Management L.P. acquired a new stake in Dyne Therapeutics during the first quarter worth about $140,666,000. Artal Group S.A. increased its position in Dyne Therapeutics by 24.6% during the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares during the last quarter. California State Teachers Retirement System increased its position in Dyne Therapeutics by 29.9% during the first quarter. California State Teachers Retirement System now owns 44,784 shares of the company’s stock worth $1,271,000 after purchasing an additional 10,317 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
DYN has been the topic of a number of recent analyst reports. Chardan Capital increased their price target on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st. Piper Sandler increased their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. HC Wainwright increased their price objective on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a report on Monday, May 20th. Finally, Jefferies Financial Group increased their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, May 20th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.78.
View Our Latest Stock Analysis on DYN
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Read More
- Five stocks we like better than Dyne Therapeutics
- What is the NASDAQ Stock Exchange?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Comparing and Trading High PE Ratio Stocks
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- How to Most Effectively Use the MarketBeat Earnings Screener
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.